FDA Approves Impel NeuroPharma's Trudhesa Nasal Spray For Acute Treatment Of Migraine; Stock Surges

(RTTNews) - Impel NeuroPharma Inc. (IMPL) said that the U.S. Food and Drug Administration approved Trudhesa or dihydroergotamine mesylate nasal spray (0.725 mg per spray) for the acute treatment of migraine with or without aura in adults. It will be commercially available in early October 2021.

In Friday regular trading, IMPL was trading at $30.98 up $7.86 or 34.00%.

The company noted that Trudhesa will be available through Trudhesa Direct, a hassle-free pharmacy partnership and copay program. The digital pharmacy fulfilment partners, Phil Inc. and Carepoint Pharmacy, will provide electronic prescribing and automatic enrollment in the patient savings program for eligible, commercially insured patients without the need for a paper copay card.